Table 4.
Health outcomes in treatment-naïve HCV patients and matched controls
| |
HCV never treated |
Matched controls |
p-value |
||
|---|---|---|---|---|---|
| |
(n = 139) |
(n = 139) |
|
||
| M | SD | M | SD | ||
| Work productivity & activity impairment | |||||
| Absenteeism |
6.67% |
18.26% |
2.84% |
13.36% |
.157 |
| Presenteeism |
24.84% |
30.07% |
12.86% |
21.28% |
.006 |
| Overall work impairment |
28.65% |
32.94% |
14.75% |
24.57% |
.004 |
| Activity impairment |
31.73% |
30.57% |
29.28% |
31.48% |
.374 |
| Healthcare resource utilization | |||||
| Physician visits |
19.54 |
24.62 |
12.06 |
16.80 |
.001 |
| ER visits |
0.46 |
1.90 |
0.35 |
1.15 |
.986 |
| Hospitalizations |
0.36 |
1.16 |
0.19 |
0.99 |
.120 |
| Quality of life (SF-12v2) | |||||
| MCS |
44.72 |
10.43 |
45.93 |
11.64 |
.361 |
| PCS |
43.49 |
10.26 |
45.99 |
10.72 |
.048 |
| Health utility | 0.68 | 0.13 | 0.71 | 0.15 | .080 |
Comparisons of work productivity impairment are based on 65 treatment-naïve HCV patients and 65 matched controls. All other comparisons include the entire samples.